Donor Genotype Effect
The concept of a 'donor genotype effect' refers to the influence an individual's unique genetic makeup has on their observable characteristics (phenotypes) or on the biological processes being studied. In genetic research, particularly Genome-Wide Association Studies (GWAS), this effect is central to identifying genetic variants associated with various traits and diseases. It underscores that the genetic material provided by a study participant directly contributes to the observed outcomes, from molecular levels to complex disease susceptibility. Researchers analyze thousands of genetic markers, such as single nucleotide polymorphisms (SNPs), to uncover these associations.
Biological Basis
At its core, the donor genotype effect is rooted in the molecular biology of DNA. Variations in the DNA sequence, such as SNPs, can alter gene function, protein structure, or gene expression levels. These changes can range from subtle modifications affecting metabolic pathways to significant alterations influencing disease pathology. For instance, specific alleles at a given SNP might lead to a dysfunctional protein, an altered binding site for a regulatory factor, or a change in the efficiency of a biochemical reaction. These genetic differences can manifest as variations in disease risk, response to environmental factors, or the levels of various biomarkers.
Clinical Relevance
Understanding the donor genotype effect is critical for precision medicine and public health. Identifying genetic variants that predispose individuals to certain diseases, influence drug response, or predict disease progression allows for tailored prevention strategies, diagnostic tools, and therapeutic interventions. For example, genetic studies aim to link specific genotypes to conditions like subclinical atherosclerosis, variations in lipid concentrations, or persistent fetal hemoglobin, providing insights into individual risk profiles and potential treatment targets. Accurate genotyping methods and rigorous quality control, including checks for minor allele frequency, call rates, and Hardy-Weinberg Equilibrium, are essential to ensure the reliability of these findings. [1]
Social Importance
The study of donor genotype effects carries significant social implications. It contributes to a deeper understanding of human diversity and the genetic basis of health and disease across populations. While offering immense potential for improving health outcomes, it also raises considerations regarding genetic privacy, equitable access to genetic testing and therapies, and the responsible use of genetic information. By advancing our knowledge of how individual genotypes shape health, this field informs public health initiatives and ethical guidelines for genetic research and applications.
Methodological and Statistical Constraints
The interpretation of donor genotype effects is subject to several methodological and statistical limitations inherent in large-scale genetic association studies. Many studies face challenges with statistical power, particularly for detecting genetic variants with modest effect sizes, given the rigorous thresholds required to correct for the extensive multiple testing undertaken in genome-wide scans. [2] Moreover, initial genotyping arrays often provide only partial coverage of the genome, which can lead to missing true associations due to a lack of linkage disequilibrium with the genotyped single nucleotide polymorphisms (SNPs) or by overlooking multiple causal variants within a single gene. [3] This incomplete coverage, coupled with the reliance on imputation methods that infer genotypes based on reference panels, introduces a degree of uncertainty and may not fully capture the complex genetic architecture underlying traits. [4]
Replication of findings across independent cohorts is crucial but can be challenging, with studies sometimes failing to replicate previously reported associations or observing differing effect sizes. [2] Such discrepancies can arise from differences in study design, genotyping platforms, or population-specific genetic architectures. Furthermore, analyses often make assumptions about the accuracy of estimated phenotypic variance and heritability when calculating the proportion of genetic variance explained by SNPs, which can influence the perceived impact of identified variants. [5] The practice of pooling data from both sexes to avoid exacerbating multiple testing concerns may also mask important sex-specific genetic effects that could otherwise provide deeper insights into trait biology. [3]
Generalizability and Phenotypic Measurement Issues
A significant limitation affecting the generalizability of findings pertains to the demographic characteristics of the study populations. Many large-scale genetic studies, including those reviewed, have primarily involved individuals of European descent. [6] This demographic homogeneity restricts the direct applicability of the results to other ethnic groups and may not capture genetic variations or environmental interactions that are more prevalent or impactful in non-European populations. Additionally, the reliance on volunteer participants can introduce a selection bias, as volunteers may not constitute a truly random sample of the general population, potentially affecting the representativeness of the observed genetic associations. [5]
Specific challenges also arise from the nature of phenotype measurement. For instance, traits averaged over extended periods, sometimes spanning decades, can be problematic due to changes in measurement equipment and potential misclassification over time. [2] Such averaging implicitly assumes that the same genetic and environmental factors influence traits consistently across a wide age range, an assumption that may obscure age-dependent genetic effects. The use of samples from specific populations, such as twins, while powerful for certain genetic analyses, may also limit the direct generalizability of findings to the broader non-twin population, although evidence for major phenotypic differences between twins and non-twins for many traits is often lacking. [5]
Complex Genetic Architecture and Environmental Confounding
The genetic architecture of complex traits is intricate, involving numerous genetic variants that interact with each other and with environmental factors, a complexity not always fully addressed. Many studies acknowledge but do not extensively investigate gene-environment interactions, meaning that context-specific genetic effects modulated by environmental influences may be overlooked. [2] For example, the effect of a genetic variant on a phenotype might differ based on dietary habits or other lifestyle factors. Furthermore, while efforts are made to account for population stratification and cryptic relatedness through methods like genomic control, these factors can still subtly influence association statistics, particularly in heterogeneous cohorts. [7]
The concept of "missing heritability" highlights that the identified genetic variants often explain only a fraction of the total heritable variation for a given trait, leaving a substantial portion unexplained. This gap suggests that many other genetic factors, such as rare variants, structural variations, or complex epistatic interactions, may contribute to the phenotype but remain largely undetected by current genome-wide association study designs. The differences in genotyping platforms and quality control procedures across various cohorts can also introduce variability and limit the consistency of findings in meta-analyses, complicating the comprehensive understanding of donor genotype effects. [6]
Variants
Genetic variants play a crucial role in shaping individual traits and disease susceptibilities, with their effects often explored through large-scale genomic studies. [8] These studies aim to identify single nucleotide polymorphisms (SNPs) that are statistically associated with various phenotypes, providing insights into underlying biological mechanisms. The donor genotype, referring to the genetic makeup of an individual, can significantly influence the expression and function of genes, thereby affecting a wide array of physiological processes and clinical outcomes. [9]
Several variants are implicated in fundamental cellular processes, including protein processing and mitochondrial function. The region encompassing THRAP3P1 and STT3B with variant rs80000774 is notable due to STT3B's role as a core component of the oligosaccharyltransferase (OST) complex, essential for N-linked glycosylation in the endoplasmic reticulum. This critical post-translational modification influences protein folding, stability, and function, impacting processes from immune responses to cell signaling. Changes at rs80000774 could alter STT3B expression or splicing, thereby affecting the efficiency of protein glycosylation and potentially influencing various physiological traits . Similarly, ATAD3B with rs1695847 encodes a mitochondrial protein vital for mitochondrial dynamics, energy production, and lipid metabolism. Variations like rs1695847 may impact mitochondrial integrity or activity, affecting metabolic health and cellular stress responses. The donor genotype effect for such variants is particularly relevant where mitochondrial function is a key determinant, such as in metabolic disorders. [10] Another key player in protein handling is SEC63, associated with rs6906957, which is involved in translocating proteins into the endoplasmic reticulum. Alterations from rs6906957 could impair protein import, leading to ER stress and potentially contributing to diseases influenced by protein trafficking and ER function. [1]
Beyond protein processing, other variants influence transcriptional regulation, non-coding RNA functions, and neural development. ARID5B (rs79498125) encodes a DNA-binding protein involved in transcriptional regulation and adipogenesis, with rs79498125 potentially affecting its regulatory activity and impacting gene expression patterns critical for cell differentiation and metabolic traits. [6] The long intergenic non-coding RNA LINC02628 (rs2167710) and the region involving RNU6-679P and LINC01194 (rs32250) represent non-coding elements. LincRNAs regulate gene expression, and variants within them, like rs2167710 and rs32250, could alter their stability or interactions, subtly influencing gene regulatory networks and complex traits. [11] MDGA2 (rs72676686), a cell adhesion molecule highly expressed in the brain, plays a crucial role in synapse formation and neural circuit organization. Variant rs72676686 may affect MDGA2's function, with donor genotype implications for neurodevelopmental traits and conditions involving altered neuronal connectivity. [8]
Further variants are associated with signaling pathways, cell growth, and stress responses. PCNX4 (rs79076914), although less characterized, may be involved in cell growth and differentiation, particularly in neural contexts. The rs79076914 variant could subtly modulate cell proliferation and survival pathways, affecting developmental or physiological traits. [9] PAK5 (rs112714481), a p21-activated kinase, is critical for cytoskeletal dynamics, cell motility, and neuronal plasticity, especially in the brain. The rs112714481 variant might alter PAK5 activity or expression, impacting cellular responses to stimuli and traits related to neurological function. [12] Lastly, the CRHBP - AGGF1 region, including rs1651094, involves two distinct genes: CRHBP modulates the body's stress response, while AGGF1 is crucial for angiogenesis. Variant rs1651094 could influence the expression or function of either gene, affecting stress hormone regulation, cardiovascular health, or metabolic regulation, highlighting the interconnectedness of these biological systems. [13]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs72676686 | MDGA2 | donor genotype effect measurement |
| rs80000774 | THRAP3P1 - STT3B | donor genotype effect measurement |
| rs1695847 | ATAD3B | donor genotype effect measurement |
| rs79498125 | ARID5B | donor genotype effect measurement |
| rs2167710 | LINC02628 | donor genotype effect measurement |
| rs79076914 | PCNX4 | donor genotype effect measurement |
| rs6906957 | SEC63 | donor genotype effect measurement |
| rs32250 | RNU6-679P - LINC01194 | donor genotype effect measurement |
| rs112714481 | PAK5 | donor genotype effect measurement |
| rs1651094 | CRHBP - AGGF1 | donor genotype effect measurement |
Defining Genetic Influence on Phenotypes
The 'donor genotype effect' refers to the measurable influence of an individual's specific genetic makeup, or genotype, on various observable characteristics and physiological measurements, known as phenotypes or traits. In the context of genome-wide association studies (GWAS), this effect is operationally defined as the statistical association between specific genetic variants, such as Single Nucleotide Polymorphisms (SNPs), and a particular trait. The conceptual framework for understanding these effects encompasses both direct genetic contributions and complex interactions with environmental or other biological factors. Identifying these genetic influences is crucial for understanding the biological pathways underlying diverse health-related traits, from metabolic parameters to cardiovascular measures. [14]
Models of Genetic Action and Environmental Interaction
Genetic effects are primarily classified through various statistical models, with the additive genetic model being a common approach; this model tests whether a trait changes by equal amounts with each additional allele across the three possible genotypes. [8] A significant classification within genetic analysis involves gene-environment interactions, where the impact of a genotype on a trait is modified by environmental variables or other individual characteristics. These interactions are explored with a range of covariates, including sex, use of oral contraceptives, overweight status (BMI > 25), gestational age (pre-term or term), birth BMI, and early growth. [14] For binary covariates, interaction is evaluated by comparing the effect size of genetic loci in the two distinct groups, whereas continuous covariates are analyzed using linear regression models that incorporate an interaction term. [14]
Standardized Assessment and Classification of Traits
The assessment of traits influenced by genotype relies on rigorous measurement approaches and operational definitions to ensure consistency and comparability across studies. Phenotypes such as metabolic traits (e.g., triglycerides (TG), HDL, LDL, C-reactive protein (CRP), glucose (GLU), insulin (INS), body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP)), echocardiographic dimensions, exercise responses, and biomarker levels (e.g., natriuretic peptides, vitamin K, vitamin D, inflammatory markers, serum urate, glycated hemoglobin, fetal hemoglobin) are quantified using standardized instruments and laboratory assays. [14] Operational definitions include specific criteria for participant eligibility, such as requiring overnight fasting for blood samples and excluding individuals who are diabetic, pregnant, or on certain medications. [14] Traits are frequently adjusted for covariates like age, sex, oral contraceptive use, pregnancy status, smoking status, and medication use to isolate genetic effects. [14] Furthermore, data transformation (e.g., natural log transformation for TG, BMI, INS, GLU, CRP, fetal hemoglobin) and dichotomization based on clinical cut-off values (e.g., BMI > 25 for overweight, LipoproteinA at 14 mg/dl for high levels, or median values for traits below detection limits) are common practices for analysis. [14]
Key Terminology in Genetic Association Studies
The terminology used to describe donor genotype effects and their investigation is precise and standardized within genetic research. A fundamental term is Single Nucleotide Polymorphism (SNP), which denotes a variation at a single position in the DNA sequence, serving as a primary target for genetic association studies. [2] A Genome-Wide Association Study (GWAS) represents the comprehensive methodology employed to systematically scan an individual's entire genome for SNPs and other genetic variants that are statistically linked to specific traits. [14] Variables accounted for in statistical models to prevent confounding, such as age, sex, oral contraceptive use, pregnancy status, and BMI, are referred to as "covariates". [14] Software packages like PLINK are commonly used for implementing statistical analyses, including interaction tests. [14] To manage the vast number of statistical tests performed in GWAS, methods such as Bonferroni correction or the estimation of a genomic control parameter are applied to establish appropriate thresholds for "genome-wide significance". [2] Genetic imputation, often facilitated by reference panels like HapMap, is employed to infer ungenotyped SNPs and enhance comparative analyses across different studies. [15]
Biological Background: Donor Genotype Effect
The genetic makeup of an individual, or donor genotype, plays a fundamental role in shaping a wide array of biological traits and processes, from basic cellular functions to complex disease susceptibility. Genome-wide association studies (GWAS) have identified numerous genetic variations, primarily single nucleotide polymorphisms (SNPs), that are associated with quantitative traits and disease phenotypes. These associations reveal how specific genetic differences can influence the molecular pathways, regulatory networks, and physiological functions that define an individual's health and predispositions.
Genetic Control of Molecular Pathways and Biomolecule Function
An individual's genotype dictates the blueprint for their cellular machinery, influencing the function of critical biomolecules and the intricate pathways they orchestrate. Genetic variants, particularly SNPs, can alter gene expression patterns or the structure and activity of proteins, enzymes, and receptors. For instance, the HNF1A gene, encoding hepatocyte nuclear factor-1 alpha, a crucial transcription factor, has polymorphisms associated with C-reactive protein levels, demonstrating how genetic variation in a regulatory protein can impact inflammatory signaling. [16] Similarly, variants in the HK1 (hexokinase 1) gene, which codes for an enzyme involved in glucose metabolism, are associated with glycated hemoglobin, highlighting a direct link between genotype, enzyme function, and metabolic pathways. [12] Even fundamental blood group antigens, determined by the ABO gene, exhibit functional polymorphisms that can be linked to various physiological outcomes. [8] The broader impact of genotype extends to global gene expression, where specific genetic loci can influence the overall transcriptional landscape of cells. [17]
Genetic Influences on Hematological and Hemostatic Processes
Donor genotype significantly impacts the characteristics of blood and its clotting mechanisms, which are vital for oxygen transport, immune defense, and preventing excessive bleeding. Genetic variations can lead to measurable differences in hematological phenotypes such such as hemoglobin, mean corpuscular hemoglobin, red blood cell count, and white blood cell count. [3] Beyond cell counts, the intricate processes of hemostasis are also under genetic control. Polymorphisms can affect the levels and activity of key hemostatic factors like fibrinogen, tissue plasminogen activator (tPA), and von Willebrand factor (vWF), as well as the efficiency of platelet aggregation induced by various stimuli. [3] A compelling example of genotype influencing a critical blood disorder is the association of the BCL11A gene with persistent fetal hemoglobin, which can ameliorate the severe phenotype of beta-thalassemia by compensating for defective adult hemoglobin production. [7]
Genotype-Mediated Regulation of Metabolic Homeostasis
The maintenance of metabolic balance, or homeostasis, is profoundly influenced by an individual's genetic profile, with implications for a wide range of health outcomes. Genetic variants contribute to the observed variability in lipid levels, including low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides, which are critical biomarkers for cardiovascular disease risk. [10] Beyond lipids, genotype also affects other key metabolic indicators, such as uric acid concentration, a primary determinant of gout risk. [4] Furthermore, the genetic background influences the body's vitamin status, including phylloquinone concentrations for vitamin K and 25(OH)D concentrations for vitamin D, underscoring the broad reach of genetic regulation over nutrient processing and utilization. [13] These genetic predispositions to metabolic dysregulation can significantly influence an individual's susceptibility to chronic metabolic conditions.
Genetic Drivers of Inflammation and Disease Pathophysiology
An individual's genetic makeup plays a crucial role in shaping their inflammatory responses and overall disease susceptibility, impacting various pathophysiological processes. Donor genotype influences the levels of numerous inflammatory markers, including CD40 Ligand, osteoprotegerin, P-selectin, tumor necrosis factor receptor 2, and tumor necrosis factor-α, all of which are integral components of the immune system's signaling pathways. [13] Genetic variations within chemokine gene clusters, such as CCL18-CCL3-CCL4, have been shown to modulate the body's response to pathogens, influencing susceptibility to infections like HIV-1 and affecting the progression of associated diseases. [18] These genetic determinants of inflammatory profiles can disrupt homeostatic mechanisms, contributing to the development and progression of complex diseases, including subclinical atherosclerosis, where chronic inflammation is a key pathological feature. [1]
Genetic Influence on Metabolic Homeostasis
Genetic variants play a crucial role in shaping the metabolic profile of individuals by influencing the homeostasis of key metabolites. These polymorphisms can lead to distinct "metabotypes," which are characteristic metabolic make-ups determined by an individual's genotype. [19] For instance, common genetic variations in genes like FADS1 are associated with different levels of unsaturated fatty acids, directly impacting lipid metabolism. [19] Similarly, polymorphisms in LIPC are linked to modifications in HDL cholesterol levels, highlighting how genetic factors regulate critical components of energy and lipid metabolism. [19]
Regulation of Gene Expression and Enzyme Function
The effect of a donor's genotype on metabolic pathways often stems from its impact on gene regulation and the functional efficiency of enzymes. Genetic variations can alter the expression levels of genes, leading to an over- or under-production of specific enzymes or transporters, thereby affecting metabolic flux. For example, deficiencies in enzymes encoded by genes such as SCAD and MCAD, caused by specific polymorphisms, are known to result in severe systemic disorders characterized by dysregulated catabolism and energy metabolism. [19] Beyond expression, genetic variants can also induce changes in protein structure, altering enzyme activity, substrate affinity, or stability through mechanisms like post-translational modifications or allosteric control, ultimately modulating the rate of metabolic reactions.
Interconnected Metabolic Networks and Signaling
Genetic variations do not operate in isolation but rather exert their effects within an intricate human metabolic network, influencing multiple interconnected pathways and signaling cascades. A change in one genetically determined metabolic pathway can propagate through the network, affecting the availability of substrates or cofactors for other pathways, leading to pathway crosstalk. This systems-level integration means that a genetic variant impacting, for example, lipid metabolism, can indirectly influence carbohydrate utilization or amino acid synthesis through network interactions. [19] The comprehensive analysis of metabolomics alongside genetic data allows for a more detailed probing of these complex network interactions and the hierarchical regulation that governs metabolic homeostasis.
Genetically Determined Disease Susceptibility
The donor genotype effect directly contributes to an individual's susceptibility to various diseases by causing pathway dysregulation. Genetically determined metabotypes can indicate an increased risk for specific medical phenotypes, as seen with LIPC polymorphisms influencing HDL cholesterol and potentially contributing to HDL-related diseases. [19] Furthermore, genetic loci associated with uric acid concentration, such as SLC2A9, directly influence the risk of conditions like gout, demonstrating a clear link between inherited metabolic traits and disease etiology. [4] Understanding these genotype-phenotype relationships also offers insights into potential therapeutic targets and enables a more personalized approach to health care, including tailored drug treatments and nutritional interventions based on an individual's genetic and metabolic profile. [19]
Genetic Insights into Disease Risk and Prognosis
Donor genotype effects offer significant prognostic value by identifying individuals predisposed to various cardiometabolic conditions. For instance, newly identified genetic loci influencing blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or triglycerides are directly associated with an increased risk of coronary artery disease. [20] Similarly, specific genetic variants are linked to uric acid concentrations, thereby predicting an individual's susceptibility to gout. [4] The association of genes like HK1 with glycated hemoglobin levels in non-diabetic populations suggests a genetic predisposition that could inform the long-term risk for metabolic dysfunction and diabetes progression. [12]
Beyond metabolic traits, genotype effects can also predict disease progression and treatment response in specific conditions. For example, a genome-wide association study revealed that BCL11A is associated with persistent fetal hemoglobin, which is known to ameliorate the phenotype of beta-thalassemia. [7] This genetic insight can help predict the severity of beta-thalassemia and potentially guide therapeutic expectations. Furthermore, polymorphisms in genes such as HNF1A are associated with C-reactive protein levels, an inflammatory biomarker with prognostic implications for various chronic diseases. [16]
Genotype-Informed Clinical Management and Personalized Medicine
The understanding of donor genotype effects provides valuable clinical applications, particularly in diagnostic utility and refined risk assessment. Genetic variations influencing biomarkers like serum urate, lipids, hemostatic factors, and subclinical atherosclerosis can serve as diagnostic indicators for underlying predispositions to conditions such as dyslipidemia, cardiovascular disease, and hematological disorders. [21] Integrating these genetic markers into risk assessment models allows for a more personalized evaluation of an individual's likelihood of developing specific diseases, moving beyond traditional clinical risk factors. This enhanced risk stratification can identify high-risk individuals who may benefit from early intervention or more aggressive management strategies.
Leveraging donor genotype information can also refine treatment selection and optimize monitoring strategies, ushering in personalized medicine approaches. For conditions like beta-thalassemia, knowledge of BCL11A variants could potentially inform clinicians about an individual's likely response to therapies aimed at increasing fetal hemoglobin, thereby guiding treatment choices. [7] Similarly, for individuals with genetic predispositions to elevated C-reactive protein or dyslipidemia, genotype-informed monitoring plans could be implemented, allowing for timely adjustments to lifestyle or pharmacotherapy. This proactive approach based on an individual's genetic profile supports prevention strategies tailored to their unique biological landscape. [15]
Genetic Associations with Comorbidities and Overlapping Phenotypes
Donor genotype effects frequently highlight the interconnectedness of various physiological systems and their associated comorbidities, revealing overlapping phenotypes. For instance, genetic loci associated with lipid concentrations are directly linked to the risk of coronary artery disease, demonstrating a clear association between metabolic disturbances and cardiovascular outcomes. [20] The discovery of genes influencing glycated hemoglobin in non-diabetic populations suggests a genetic basis for metabolic dysregulation that may precede overt diabetes, potentially overlapping with features of metabolic syndrome. [12] These genetic associations underscore the importance of considering a broader spectrum of health outcomes when evaluating an individual's genetic risk.
Furthermore, genetic research often illuminates how a single genotype effect can contribute to complex, sometimes syndromic, presentations or increase susceptibility to multiple related conditions. The association of specific genetic loci with both uric acid concentration and the risk of gout exemplifies how genetic factors can drive a direct disease outcome while also indicating a predisposition to related metabolic imbalances. [4] Studies on hemostatic factors, hematological phenotypes, and subclinical atherosclerosis also reveal intricate genetic underpinnings that contribute to a spectrum of cardiovascular and thrombotic disorders. [3] Recognizing these broader genetic associations is crucial for comprehensive patient care and the development of integrated prevention strategies.
References
[1] O'Donnell, C. J. et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8, no. Suppl 1, 2007, p. S10. PMID: 17903303.
[2] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 17903301, 2007.
[3] Yang, Q. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, no. S1, 2007.
[4] Dehghan, A. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, vol. 372, no. 9654, 2008, pp. 1959-1965.
[5] Benyamin, B., et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." Am J Hum Genet, vol. 84, no. 1, 2009, pp. 60-65.
[6] Aulchenko, Y. S. et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47-55. PMID: 19060911.
[7] Uda, M. "Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia." Proc Natl Acad Sci U S A, vol. 105, no. 6, 2008, pp. 1620-1625.
[8] Melzer, D. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, vol. 4, no. 5, 2008.
[9] Wilk, JB. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Med Genet, vol. 8, no. S1, 2007, p. S8.
[10] Kathiresan, S. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[11] Li, S. "The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts." PLoS Genet, vol. 3, no. 11, 2007.
[12] Pare, G. "Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study." PLoS Genet, vol. 4, no. 12, 2008.
[13] Benjamin, E. J. et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, vol. 8, no. Suppl 1, 2007, p. S11. PMID: 17903293.
[14] Sabatti, C., et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, 19060910, 2008.
[15] Willer, C. J., et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, 18193043, 2008.
[16] Reiner, A. P. et al. "Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein." Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1199-205. PMID: 18439552.
[17] Dixon, A. L. et al. "A whole-genome association study of global gene expression." Nat Genet, 2007.
[18] Modi, W. S. et al. "Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression." Am J Hum Genet, vol. 79, 2006.
[19] Gieger, Christian, et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genetics, vol. 4, no. 11, 2008, e1000282.
[20] Kathiresan, S. et al. "Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans." Nat Genet, vol. 40, no. 2, 2008, pp. 189-97. PMID: 18193044.
[21] Wallace, C. et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." Am J Hum Genet, vol. 82, no. 1, 2008, pp. 139–149. PMID: 18179892.